Neurocrine Biosciences Reports Mixed Q4
Neurological therapeutics specialist Neurocrine Biosciences (NASDAQ:NBIX) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted earnings per share (EPS) beat estimates significantly.
Overall, the quarter showcased strong performance, particularly from the flagship prescription medication Ingrezza, underscoring the effectiveness of its strategic initiatives.
Source: Neurocrine Biosciences. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year. SG = Selling, general, and administrative expenses
Source Fool.com
Neurocrine Bioscience Stock
€131.10
0.460%
With 48 Buy predictions and not a single Sell prediction Neurocrine Bioscience is an absolute favorite of our community.
With a target price of 148 € there is a slightly positive potential of 12.89% for Neurocrine Bioscience compared to the current price of 131.1 €.
